Meftal DS Tablets

MEFTAL-SPAS® DS Tablet

MEFTAL-SPAS® DS is a double-strength antispasmodic and analgesic formulation indicated for the symptomatic relief of smooth muscle spasms and associated visceral pain.

Clinical Applications

Dysmenorrhea

Dysmenorrhea

Learn More
Intestinal Colic

Intestinal Colic

Learn More
Renal Colic

Renal Colic

Learn More
Biliary Colic

Biliary Colic

Learn More

More Clinical Applications

Gynaecology Primary dysmenorrhea, relief of intense uterine contractions and pelvic pain requiring a higher-strength dose.
Gastroenterology Intestinal colic and spasmodic pain associated with enteritis or colitis requiring stronger relief.
Urology Renal colic and ureteric spasms caused by calculi or infection.
Hepatobiliary Biliary colic and spasms of the gallbladder or bile ducts.

Prescribing Guidelines by Age

MEFTAL-SPAS® product range is formulated to provide age-appropriate dosing across the patient lifecycle. The DS Tablet is a higher-strength option reserved for adults needing stronger relief.

Patient Age Group Recommended Format Typical Clinical Use
Adults Tablet Monthly period pain and functional GI spasms; biliary, renal, and intestinal colic.

Pharmacological Highlights for the Physician

  • Dual Mechanism :
    Combines the anticholinergic effect of Dicyclomine HCl (to stop the spasm) with the anti-prostaglandin effect of Mefenamic Acid (to stop the pain).
  • Rapid Absorption :
    Optimized for quick onset
  • Proven Safety :
    Established clinical profile with over three decades of trusted use in the Indian healthcare ecosystem.

Prescribing Information

Generic Name

Mefenamic Acid and Dicyclomine Hydrochloride Tablets IP

(Brand Name: MEFTAL-SPAS ® DS Tablets)

Qualitative and Quantitative Composition

MEFTAL-SPAS® DS Tablets

Each uncoated tablet contains:

Mefenamic Acid IP: 500 mg

Dicyclomine Hydrochloride IP: 20 mg

Colour: Tartrazine.

Dosage Form and Strength

Dosage Form: Tablets.

Dosage Strength: Mefenamic acid 500 mg + Dicyclomine Hydrochloride 20 mg per tablet.

Posology and Method of Administration

For oral administration in adults.

  • MEFTAL-SPAS® DS Tablets

    As prescribed by the physician.

Treatment is generally required till the time dysmenorrhea symptoms persist, i.e., 3 to 5 days during the menses, and should not be continued beyond 7 days without medical supervision. MEFTAL-SPAS® DS Tablets should be taken preferably with or after food, or as prescribed by the physician.

Contraindications

MEFTAL-SPAS® DS Tablets are contraindicated in the following

  • Known hypersensitivity to mefenamic acid or to dicyclomine or to any component of the formulation.
  • Pre-existing asthma and aspirin-sensitive asthma.
  • Active ulceration/bleeding or chronic inflammation of upper or lower gastrointestinal (GI) tract.
  • Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • Pre-existing renal disease/obstructive uropathy.
  • Glaucoma.
  • Myasthenia gravis.
  • Last trimester of pregnancy.
  • Lactation.
  • Inflammatory bowel disease, paralytic ileus and intestinal atony.

Possible Side Effects (Safety Information)

For detailed quantitative, and qualitative composition, therapeutic indications, posology and method of administration, contraindications, special warnings and precautions for use, drug interactions, undesirable effects, overdose, mechanism of action, pharmacodynamic properties of MEFTAL-SPAS® DS Tablets, download the note.